IRIS
GARIPOLI, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.568
NA - Nord America 2.525
AS - Asia 1.390
SA - Sud America 404
AF - Africa 54
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 7.945
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.489
RU - Federazione Russa 1.685
SG - Singapore 588
CN - Cina 448
SE - Svezia 440
IE - Irlanda 377
IT - Italia 367
BR - Brasile 349
DE - Germania 144
HK - Hong Kong 135
GB - Regno Unito 116
UA - Ucraina 105
FR - Francia 99
PL - Polonia 85
FI - Finlandia 57
VN - Vietnam 57
IN - India 49
BE - Belgio 21
ZA - Sudafrica 17
CA - Canada 15
NL - Olanda 14
AR - Argentina 13
BD - Bangladesh 13
ES - Italia 12
ID - Indonesia 12
IQ - Iraq 12
CO - Colombia 11
MX - Messico 11
JP - Giappone 10
MA - Marocco 10
VE - Venezuela 10
EC - Ecuador 8
PK - Pakistan 8
TR - Turchia 7
IL - Israele 5
IR - Iran 5
JM - Giamaica 5
PH - Filippine 5
SI - Slovenia 5
AT - Austria 4
CZ - Repubblica Ceca 4
EG - Egitto 4
ET - Etiopia 4
KE - Kenya 4
PT - Portogallo 4
SA - Arabia Saudita 4
TN - Tunisia 4
UY - Uruguay 4
UZ - Uzbekistan 4
AO - Angola 3
AZ - Azerbaigian 3
GR - Grecia 3
JO - Giordania 3
MY - Malesia 3
OM - Oman 3
RO - Romania 3
RS - Serbia 3
TH - Thailandia 3
AL - Albania 2
BO - Bolivia 2
BY - Bielorussia 2
CL - Cile 2
DZ - Algeria 2
EE - Estonia 2
EU - Europa 2
GE - Georgia 2
HU - Ungheria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LV - Lettonia 2
NO - Norvegia 2
NP - Nepal 2
PA - Panama 2
PE - Perù 2
PS - Palestinian Territory 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BW - Botswana 1
BZ - Belize 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CM - Camerun 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GT - Guatemala 1
KR - Corea 1
LT - Lituania 1
LY - Libia 1
MD - Moldavia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
SR - Suriname 1
TW - Taiwan 1
Totale 7.945
Salva come PNG Salva come JPEG
Città #
Moscow 458
Dublin 377
Chandler 344
Ashburn 326
Singapore 314
Dallas 278
Nyköping 218
Jacksonville 209
Beijing 157
Hong Kong 135
San Jose 134
Messina 85
Warsaw 80
Ann Arbor 72
Dearborn 69
The Dalles 66
Los Angeles 58
Princeton 55
Medford 53
New York 50
Cambridge 47
Lauterbourg 45
Des Moines 42
Boardman 31
Lancaster 30
Munich 30
Buffalo 25
Jinan 23
Brussels 21
Ho Chi Minh City 21
Rome 21
São Paulo 21
Tianjin 20
Woodbridge 20
Frankfurt am Main 19
Pune 18
Shenyang 16
Orem 15
Rio de Janeiro 15
Brooklyn 14
Milan 14
Hebei 13
Guangzhou 12
Johannesburg 12
Wilmington 12
Redondo Beach 11
San Mateo 11
Chicago 10
Haikou 10
Hangzhou 10
London 10
Nanchang 10
Zhengzhou 10
Catania 9
Manchester 9
Turku 9
Düsseldorf 8
Leawood 8
Nanjing 8
Stockholm 8
Tokyo 8
Trento 8
Atlanta 7
Augusta 7
Changsha 7
Chennai 7
Hanoi 7
Lanzhou 7
Ningbo 7
Santa Clara 7
Taizhou 7
Belo Horizonte 6
Dong Ket 6
Jakarta 6
Montreal 6
Porto Alegre 6
Ribeirão Preto 6
Shanghai 6
São Bernardo do Campo 6
Amsterdam 5
Brasília 5
Denver 5
Montes Claros 5
Murska Sobota 5
Paris 5
Redwood City 5
Shenzhen 5
Addis Ababa 4
Bogotá 4
Bragança Paulista 4
Casablanca 4
Contagem 4
Edinburgh 4
Goiânia 4
Guarulhos 4
Helsinki 4
Hyderabad 4
Jiaxing 4
Montevideo 4
Mumbai 4
Totale 4.455
Salva come PNG Salva come JPEG
Nome #
RESEZIONE DI METASTASI EPATICHE DA CANCRO DEL COLON DOPO "SHRINKAGE" DI MALATTIA OTTENUTO CON FOLFIRI + CETUXIMAB 278
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 229
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 222
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 219
Incidence and Outcomes of Bone Metastases. Evaluation of BTAs Therapy, Pain Relief and Quality of Life: Experience from a Single Cancer Center 202
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 200
Endoscopic mucosal resection of a large inflammatory fibroid polyp (Vanek's tumor): a case report 199
"Young-old",Old-old", Oldest-old" and breast cancer: Cancer surrender prohibited. Our challenge for 87 patients 197
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 196
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 184
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 182
Esperienze cliniche in oncologia:Donna affetta da crcinoma del pancreas con componente neuroendocrina funzionante 182
A randomized factorial trial of sequential doxrubicina and CMF vs CMF and chemoterapy alone vs chemoterapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer 180
Thyroid gland metastasis from breast cancer as sixth site of disease:A Case Report 180
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 180
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen 178
Amifostine in conjuction with G-CSF enhances chemoterapy mobilization of peripheral blood progenitor cell 174
Men with Breast Cancer: 15 Cases 172
gemcitabine and pegylated liposomial doxorubicin in recurrent epithelial ovarian cancer (REOC).Preliminary report a phase II study 170
Breast. La terapia primaria: stato dell'arte 169
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications. 169
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 165
Il ruolo dell'ormonoterapia nel carcinoma della mammella in eta' geriatrica 163
Second line chemoterapy in patients with metastatic colorectal cancer(MCRC):our experience 162
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 158
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 157
CIRCULATING PLASMA CELLS IN MULTIPLE MYELOMA: CORRELATION WITH DISEASE STAGE 155
Sustainability of Eribulin treatment for patients with metastatic breast cancer: is the cost of the drug related to the benefit produced (Effectiveness and Safety)? A single center experience 155
Impact of integrated treatments on patient management in solid tumors: From diagnosis to palliative care. 146
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 146
Gemcitabine (GEM) and liposomal doxorubicin (PLD) in recurrent/metastatic breast carcinoma: A phase II study 139
Circulating plasma cells in Multiple Myeloma correlation with disease stage 137
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 136
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 136
Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. 123
ZD 1839 IRESSA IN HEAVELY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) ASSESSMENT OF TOLERABILITY AND THE CLINICAL BENEFIT 122
Resistance to PGE(2) inhibition of PWM-stimulated lymphocytes from neoplastic patients 113
L'eritropoietina nel trattamento dell'anemia associata alle sindromi mielodisplastiche 111
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications 101
Risk of burnout in a sample of oncology healthcare professionals working in a hospital oncology unit with hospice and relationship with dysfunctional metacognitive beliefs 98
The interplay between burnout risk and attachment styles among palliative care practitioners 98
Safety and clinical activity of trastuzumab (TSM) containing therapies in heavily pretreated patients with metastatic breast cancer (MBC): A five-year experience 97
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 96
Terapia con r-IL2 a basse dosi in due pazienti con leucemia mieloide cronica(LMC) in fase blastica 93
Ruolo della capecitabinanei tumori gastroentericiDalla monoterapia all'associazione nel trattamento della malattia metastatica del colon-retto:ruolo della capecitabina 90
Polycythemia vera and essential thrombocytemia treated with IFN-ALPHA2a: Evidence of a significant clinical activity and molecular response. 90
SAFETY OF PEGILATED LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN ELDERLY WOMEN (>65 YEARS)WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER 89
Temozolamide plus oral vinorelbine in the treatment of brain metastases from solid tumours in heavily pre- treated patients. 89
Southern Bloting:Tecniche ed applicazioni 88
Impiego della fish nello studio della fusione BCR-ABL in pazienti con leucemia mieloide cronica 87
Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer(MBC): a five year experience. 86
Preliminary results of a phase II study of amifostine for patients with myelodisplastic syndrome 83
Terapia con r-IL-2 a basse dosi in pazienti con mieloma multiplo(MM) sottoposti a terapia con Melphalan a dosi intermedie e reinfusione di cellule staminali periferiche 81
Mobilization of breast cancer cells after priming with cyclophosphamide and G-CSF 78
null 52
null 33
Totale 8.015
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.555
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.555
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202194 0 0 0 0 0 0 0 0 0 0 58 36
2021/2022446 3 64 20 15 13 5 24 15 5 101 56 125
2022/20231.241 92 124 56 129 85 117 23 83 470 4 44 14
2023/2024293 20 47 15 27 21 89 10 11 2 13 7 31
2024/20251.139 7 14 14 82 60 46 34 219 312 96 90 165
2025/20263.485 174 187 274 179 296 791 462 479 489 120 34 0
Totale 8.015